Data from Direct Medical Spending on Young and Average-Age Onset Colorectal Cancer before and after Diagnosis: a Population-Based Costing Study

Abstract

<div>AbstractBackground:<p>Despite a better understanding of the increasing incidence of young-onset colorectal cancer (yCRC; age at diagnosis <50 years), little is known about its economic burden. Therefore, we estimated direct medical spending on yCRC before and after diagnosis.</p>Methods:<p>We used linked administrative health databases in British Columbia, Canada, to create a study population of yCRC and average-age onset colorectal cancer (aCRC; age at diagnosis ≥50 years) cases, along with cancer-free controls. Over the 1-year period preceding a colorectal cancer diagnosis, we estimated direct medical spending on hospital visits, healthcare practitioners, and prescription medications. After diagnosis, we calculated cost attributable to yCRC and aCRC, which additionally included the cost of cancer treatments (e.g., chemotherapy and radiotherapy) across phases of care.</p>Results:<p>We included 1,058 yCRC (45.4% females; age at diagnosis 42.4 ± 6.2 years) and 12,619 aCRC (44.8% females; age at diagnosis of 68.1 ± 9.2 years) cases. Direct medical spending on the average yCRC and aCRC case during the year before diagnosis was $6,711 and $8,056, respectively. After diagnosis, the overall average annualized cost attributable to yCRC significantly differed in comparison with aCRC for the initial ($50,216 vs. $37,842; <i>P</i> < 0.001), continuing ($8,361 vs. $5,014; <i>P</i> < 0.001), and end-of-life cancer phase ($86,125 vs. $61,512; <i>P</i> < 0.001) but not end-of-life non-cancer phase ($77,273 vs. $23,316; <i>P</i> = 0.372).</p>Conclusions:<p>Reported cost estimates may be used as inputs for future economic evaluations pertaining to yCRC.</p>Impact:<p>We provided comprehensive cost estimates for healthcare spending on young-onset colorectal cancer.</p></div>